Impairment Testing and Asset Valuation - The company does not amortize intangible assets with uncertain useful lives and reviews their useful lives annually[2]. - Long-term equity investments are tested for impairment, and if recoverable amounts are below book values, impairment losses are recognized[4]. - The company conducts impairment tests on fixed assets and recognizes impairment losses if recoverable amounts are lower than book values[4]. - The company has a policy for testing impairment of intangible assets, recognizing losses when recoverable amounts fall below book values[7]. - Goodwill is tested for impairment at least annually, with losses recognized if the recoverable amount of related asset groups is below their book value[7]. - The company recognizes expected liabilities when obligations meet specific criteria, including the likelihood of economic outflow and reliable measurement[19]. - The company will recognize impairment losses for contract costs when their carrying amount exceeds the expected remaining consideration from related goods or services[26]. - The company has not reported any new impairment provisions during the period, maintaining the book value of its assets[181]. Revenue Recognition - Revenue is recognized when the company fulfills performance obligations, with specific conditions for domestic and international sales[22]. - The company allocates transaction prices to performance obligations based on standalone selling prices and recognizes revenue accordingly[22]. - The company does not apply different accounting policies for revenue recognition across similar businesses[23]. - The company recognizes contract costs based on the same basis as the revenue recognition of related goods or services, with amortization for costs not exceeding one year recorded in the current profit and loss[26]. Employee Compensation and Benefits - Short-term employee compensation is recognized as liabilities in the period services are provided, including wages, bonuses, and benefits[10]. - The company recognizes employee compensation related to accumulated paid leave rights based on expected payment amounts[12]. - The company recognizes employee benefits liabilities based on the defined contribution plan and measures them at present value using discount rates aligned with government bonds or high-quality corporate bonds[13]. - For defined benefit plans, the company estimates obligations using actuarial assumptions and discounts them to determine the present value of the obligations and current service costs[13]. - The company confirms termination benefits when it cannot unilaterally withdraw from the plan or when it recognizes costs related to restructuring[14]. - Other long-term employee benefits are measured at present value, including service costs and interest on net liabilities or assets[18]. Taxation and Deferred Tax Assets - Deferred tax assets are confirmed based on the probable taxable income, reducing the income tax expense in the current profit and loss statement[31]. - The company will recognize deferred tax assets related to deductible temporary differences from acquired entities if new information indicates realizable economic benefits within 12 months post-acquisition[31]. - The company applies the balance sheet liability method to recognize and measure deferred tax liabilities or assets based on temporary differences between the book value and tax base of assets and liabilities as of the balance sheet date[36]. - Deferred tax assets are recognized for deductible temporary differences, limited to the amount of future taxable income that is likely to be available to offset these differences[36]. - The company reviews the carrying amount of deferred tax assets at the balance sheet date and reduces the carrying amount if it is unlikely to obtain sufficient taxable income in future periods[36]. Financial Performance and Position - The company's operating revenue for the first half of 2023 was approximately CNY 4.56 billion, a decrease of 9.85% compared to the same period last year[106]. - The net profit attributable to shareholders for the same period was approximately CNY 346.78 million, down 64.24% year-on-year[106]. - The net cash flow from operating activities was approximately CNY 188.78 million, a significant decrease of 87.83% year-on-year[106]. - Total assets at the end of the reporting period reached approximately CNY 14.45 billion, an increase of 9.07% compared to the end of the previous year[106]. - The company's net assets attributable to shareholders were approximately CNY 7.79 billion, showing a slight increase of 0.61% from the previous year[106]. - The current ratio at the end of the reporting period was 1.18, down 4.07% from the previous year[107]. - The debt-to-asset ratio increased to 45.79%, up 4.59% compared to the previous year[107]. - EBITDA interest coverage ratio was 18.83, a decrease of 42.77% year-on-year[107]. Accounts Receivable and Bad Debt Provisions - The accounts receivable notes decreased by 30.86% compared to the end of 2022, primarily due to a reduction in the amount of outstanding notes[59]. - The total accounts receivable at the end of the period amounted to ¥1,247,849,913.39, with bank acceptance bills accounting for the entire amount[65]. - The company reported a total bad debt provision of ¥176,941,639.45, with a beginning balance of ¥182,887,984.73 and a provision of ¥2,662,938.47 during the period[73]. - The actual write-off of accounts receivable during the period was ¥8,609,283.75, attributed to expected uncollectibility[74]. - The aging analysis shows that accounts receivable within one year totaled ¥638,792,201.32, representing 80.0% of the total[68]. - The company has a bad debt provision ratio of 4.03% for accounts receivable aged 1-2 years, and 10.00% for those aged 2-3 years[72]. - The total balance of accounts receivable was ¥797,772,772.19, with a bad debt provision of ¥176,941,639.45, indicating a provision coverage ratio of approximately 22.15%[69]. - The company has recognized a total of ¥150,843,667.00 in bad debt provisions for specific overdue receivables, with a 100% provision rate[69]. Inventory and Prepayments - The total inventory balance as of June 30, 2023, was CNY 1,175,332,258.84, an increase from CNY 908,092,626.83 at the beginning of the period[119]. - The total prepayments at the end of the period were ¥270,518,970.65, an increase from ¥216,256,007.49 at the beginning of the period, reflecting a growth of about 25.1%[81]. - Prepayments within one year accounted for 79.20% of total prepayments, up from 76.16% at the beginning of the period[81]. Research and Development - The company’s R&D investment reached 390 million yuan, with an R&D intensity of 7.38%, and it applied for local financial subsidies amounting to 91.17 million yuan[160]. - The company has organized 81 R&D projects focusing on new product development and technology application, with a budget of 673 million yuan for the year[160]. - The company is actively investing in R&D for specialty PVA products, filling several domestic gaps in the market[144]. Market and Production Insights - The actual production of polyvinyl alcohol (PVA) in China for the first half of 2023 was approximately 400,000 tons, making it the largest producer globally[140]. - The company’s PVA product output reached 119,300 tons, with sales volume at 107,900 tons and sales revenue of 1,352.68 million yuan, with new specialty products accounting for 77.88% of sales[145]. - The company is focusing on expanding its product lines and enhancing its industrial chain, which includes the development of high-strength and high-modulus PVA fibers[145]. - The company has identified new growth opportunities in downstream industries such as optical films, PVB films, and biodegradable materials, which are experiencing rapid development[144]. Financial Management and Risk - The company has disclosed potential risks in the report, advising investors to be cautious[92]. - The report has not been audited, ensuring that the financial statements are accurate and complete[89]. - The company has confirmed no non-operating fund occupation by controlling shareholders or related parties[92]. - The company has not violated decision-making procedures for external guarantees[92]. - The company has strengthened accounts receivable collection efforts, with a focus on tracking and managing overdue accounts[165]. - The company has implemented a dual prevention system for safety and environmental management, enhancing digital management capabilities[165].

证券代码：600063 股票简称：皖维高新 编号：临 2023-018 安徽皖维高新材料股份有限公司 八届二十八次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担个别及连带责任 一、董事会会议召开情况 安徽皖维高新材料股份有限公司下设的分支机构"铁路轨道衡 计量站"成立于 2007 年 3 月 12 日，主要负责铁路轨道衡计量经营。 根据公司"腾笼换鸟"和高质量转型发展的需要，目前自营铁路已 经拆除，计量站处于停用状态。 安徽皖维高新材料股份有限公司（以下简称："公司"）董事会 八届二十八次会议于 2023 年 8 月 9 日在公司研发中心 6 楼百人会议 室召开。本次会议应到董事 9 人，实际到会 8 人，董事张正和先生 因工作原因未能出席现场会议，委托董事孙先武先生代为行使表决 权并签署相关文件。本次会议由董事长吴福胜先生主持，公司监事、 部分高级管理人员列席了会议。本次会议的召开及程序符合《中华 人民共和国公司法》和《公司章程》的有关规定。本次会议经过充 分讨论，以记名投票表决方式进行了表决，审议通过了相关议案。 ...

安徽皖维高新材料股份有限公司 2023 年度超额利润分享实施细则 一、三年目标利润规划完成情况 按照《安徽皖维高新材料股份有限公司超额利润分享方案》 要求，公司在三年计划期内目标利润计划保持稳定增长。 2023 年度净利润考核目标值为 109642 万元。 二、年度超额利润分享适用条件 1、安徽皖维高新材料股份有限公司（以下简称"皖维高新" 或"公司"）为商业一类企业，"科改示范行动"试点企业，符合 相关政策要求，具备开展超额利润分享方案条件。 2、公司年度利润创造能力与战略发展要求匹配，满足本年 度对目标利润的考核要求。 3、公司建立健全的法人治理结构，人力资源管理基础完善， 财务管理制度规范，近三年没有因财务、税收等违法违规行为受 到行政、刑事处罚。 三、2023年度目标利润计算基础 （一）年度利润考核目标 （二）按照公司上一年净资产收益率计算的利润水平 考虑相关影响因素后，按照上一年净资产收益率测算 2023 年度公司净利润为 154,604 万元（上一年净资产收益率 17.58%， 2023 年底净资产预算 879,431 万元）。 （三）近三年企业实际利润金额 2020-2022 年公司主营业务发展 ...

单位：元/吨（不含税） | 主要产品 | 2023 年半年度均价 | 2022 年半年度均价变动幅度（%） | | | --- | --- | --- | --- | | 聚乙烯醇（PVA） | 12,533.91 | 20,309.08 | -38.28 | | 醋酸乙烯 | 6,661.77 | 12,880.41 | -48.28 | | 水泥 | 296.58 | 354.23 | -16.27 | 主要产品 产量(吨) 销量(吨) 营业收入（万元） 聚乙烯醇（PVA） 119,338.44 107,921.91 135,268.37 醋酸乙烯 53,841.56 46,975.00 31,293.66 水泥 1,104,965.08 1,105,627.45 32,791.10 熟料 1,240,903.15 290,492.00 7,986.06 PVA 高强高模纤维 10,515.71 9,544.72 16,889.04 聚酯切片 31,807.68 31,140.68 26,397.72 VAE 乳液 66,907.43 47,763.93 24,937.49 可再分散性胶粉 26,605. ...

证券代码：600063 股票简称：皖维高新 编号：临 2023-019 安徽皖维高新材料股份有限公司 关于与安徽皖维先进功能膜材料研究院有限公司 签订技术服务协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担个别及连带责任 重要内容提示： ●本公司与关联方—安徽皖维先进功能膜材料研究院有限公司 围绕公司"卡脖子"技术攻关和新产品开发工作，签订了技术服务 协议。技术服务期限为 2023 年 08 月至 2024 年 12 月。本技术协议 开发的成果所有权归公司所有。技术服务费总额 687 万元，根据成 果交付进度付款。 ●本次交易构成关联交易。 ●本次交易未构成重大资产重组。 ●按《上海证券交易所股票上市规则》的有关规定，本次关联 交易无需提交股东大会审议。 一、关联交易概述 1、2023 年 8 月 9 日，公司召开八届二十八次董事会会议，审议 通过了《关于与安徽皖维先进功能膜材料研究院有限公司签订技术 服务协议的议案》。为进一步提升公司 PVB 树脂及胶片、PVA 光学 薄膜及偏光片的产品性能，促进产品更新迭代，同时也为体现 ...

2、安徽皖维先进功能膜材料研究院有限公司作为本公司关联方， 自成立以来，一直全力支持本公司的"卡脖子"技术攻关和新产品开发 工作。为进一步提升公司 PVB 树脂及胶片、PVA 光学薄膜及偏光片 的产品性能，促进产品更新迭代，同时也为体现商业公平原则，实现 公平交易，我们同意公司与皖维膜研院签订技术服务协议，并按协议 有关约定支付技术服务费 687 万元。 一、关于与安徽皖维先进功能膜材料研究院有限公司签订技术服 务协议事项的独立意见 安徽皖维高新材料股份有限公司独立董事 关于公司八届二十八次董事会相关事项的独立意见 根据中国证监会《上市公司独立董事规则》、《上市公司治理准 则》、《上海证券交易所上市规则》和《公司章程》的有关规定，我们 作为安徽皖维高新材料股份有限公司独立董事，基于独立客观原则， 对公司八届二十八次董事会的相关事项进行认真审阅及核查，并发表 如下独立意见： 我们本着审慎负责的态度，已事前审阅了《关于与安徽皖维先进 功能膜材料研究院有限公司签订技术服务协议的议案》及相关文件， 经过认真讨论，对该事项发表如下独立意见： 1、我们对《关于与安徽皖维先进功能膜材料研究院有限公司签 订技术服务协议的议案 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 2,214,893,901.96, a decrease of 12.03% compared to CNY 2,498,063,275.38 in the same period last year[3] - Net profit attributable to shareholders was CNY 129,999,395.55, down 69.52% from CNY 415,215,000.85 year-on-year[3] - Basic and diluted earnings per share were both CNY 0.059, a decline of 73.30% from CNY 0.216 in the same period last year[4] - Total operating revenue for Q1 2023 was approximately ¥2.21 billion, a decrease of 12.0% compared to ¥2.52 billion in Q1 2022[43] - Net profit for Q1 2023 was approximately ¥127.30 million, down 70.2% from ¥426.50 million in Q1 2022[44] - Earnings per share for Q1 2023 were ¥0.059, compared to ¥0.221 in Q1 2022, reflecting a decrease of 73.3%[44] - Comprehensive income for Q1 2023 was approximately ¥170.64 million, down 54.0% from ¥371.06 million in Q1 2022[44] Cash Flow - The net cash flow from operating activities decreased by 87.16% to CNY 68,420,022.62, compared to CNY 531,977,719.87 in the previous year[4] - Cash inflow from operating activities for Q1 2023 was $1,950,432,976.80, a decrease of 17.5% compared to $2,364,813,398.11 in Q1 2022[47] - Net cash flow from operating activities in Q1 2023 was $68,420,022.62, significantly lower than $532,733,983.32 in Q1 2022, reflecting a decline of 87.2%[47] - Cash inflow from financing activities in Q1 2023 was $1,354,137,269.05, up from $1,183,467,636.98 in Q1 2022, representing a growth of 14.4%[48] - Net cash flow from financing activities improved to $545,489,098.31 in Q1 2023, compared to a negative $24,462,192.67 in Q1 2022[48] - The ending cash and cash equivalents balance for Q1 2023 was $160,560,763.17, down from $373,584,461.93 in Q1 2022, a decrease of 57.0%[48] Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,510,348,816.94, an increase of 2.00% from CNY 13,245,451,815.21 at the end of the previous year[4] - Current liabilities amounted to approximately 4.84 billion, slightly increased from 4.82 billion year-over-year[12] - Total liabilities increased to approximately ¥5.55 billion in Q1 2023 from ¥5.46 billion in Q1 2022, marking a rise of 1.4%[43] - The company’s total liabilities increased to approximately 4.84 billion, reflecting a slight rise from the previous year[12] - Long-term borrowings increased by 61.54%, primarily due to an increase in long-term bank loans during the reporting period[6] - Long-term borrowings rose to 210 million from 130 million year-over-year[12] Equity and Investments - Shareholders' equity attributable to the parent company increased by 2.26% to CNY 7,922,383,728.39 from CNY 7,747,127,831.39 at the end of the previous year[4] - Total equity attributable to shareholders increased to approximately ¥7.92 billion in Q1 2023 from ¥7.75 billion in Q1 2022, an increase of 2.3%[43] - The company completed the acquisition of 100% equity in Anhui Wanwei Zhisheng New Materials Co., Ltd., which is now a wholly-owned subsidiary included in the consolidated financial statements[4] - The company reported non-recurring gains of approximately 33.70 million, primarily from asset disposals and government subsidies[23] Operational Costs - Total operating costs for Q1 2023 were approximately ¥2.10 billion, an increase of 4.3% from ¥2.02 billion in Q1 2022[43] - Research and development expenses for Q1 2023 were approximately ¥93.36 million, a decrease of 19.3% from ¥115.72 million in Q1 2022[43] - The company reported a significant decrease in financial expenses, down to approximately ¥3.44 million from ¥10.30 million in Q1 2022[43] Inventory and Cash Management - Cash and cash equivalents were approximately 3.26 billion, compared to 3.14 billion in the previous year[27] - Inventory increased to approximately 952.74 million from 888.34 million year-over-year[27] - Cash received from investment income in Q1 2023 was $554,924.06, a decline from $1,287,071.68 in Q1 2022, reflecting a decrease of 56.9%[47] - Total cash inflow from operating activities was impacted by a significant drop in cash received from other operating activities, which fell to $10,507,407.28 from $62,957,596.87 year-over-year[47] - The company paid $195,820,600.63 in cash to employees in Q1 2023, an increase of 11.3% compared to $176,051,104.36 in Q1 2022[47]

证券代码：600063 证券简称：皖维高新 编号：临 2023-011 安徽皖维高新材料股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 会议召开地点：上海证券交易所上证路演中心（网址： 投资者可于 2023 年 03 月 24 日(星期五)至 03 月 30 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 wwgfzqb888@163.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 重要内容提示： 会议召开时间：2023 年 03 月 31 日(星期五)上午 10:00-11:00 总经理兼财务负责人：孙先武 独立董事：戴新民 安徽皖维高新材料股份有限公司（以下简称"公司"）已于 2023 年 3 月 11 日发布公司 2022 年年度报告，为便于广大投资者更全面深 入了解公司 2022 年度经营成果、财务 ...

Financial Performance - The net profit attributable to the parent company's shareholders for 2022 was CNY 1,369,281,540.52, with a total distributable profit of CNY 3,017,037,597.33 after accounting for reserves and dividends[4]. - Basic earnings per share for 2022 increased by 30.77% to CNY 0.68 from CNY 0.52 in 2021[18]. - The weighted average return on net assets rose to 19.22%, an increase of 3.05 percentage points compared to the previous year[18]. - The company reported a basic earnings per share (excluding non-recurring gains and losses) of CNY 0.68, reflecting a 30.77% increase year-on-year[18]. - The total profit reached 1.516 billion RMB, an increase of 34.75% year-over-year[74]. - The net profit attributable to shareholders was approximately 1.37 billion yuan, reflecting a 37.07% increase from the previous year[66]. - The company achieved operating revenue of CNY 994,200.17 million, a year-on-year increase of 21.28%, and a net profit attributable to shareholders of CNY 136,928.15 million, up 37.07%[122]. - The company's total assets as of December 31, 2022, were CNY 1,324,545.18 million, reflecting a year-on-year growth of 9.92%[122]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 1.5 per 10 shares, totaling CNY 323,887,406.10, with remaining undistributed profits of CNY 2,693,150,191.23 carried forward[4]. - The total number of shares for dividend distribution is based on the total share capital of 2,159,249,374 shares as of December 31, 2022[4]. Revenue and Growth - The company reported a total annual revenue of CNY 10,941,000,000, reflecting a year-on-year growth of approximately 15%[46]. - The company’s operating revenue for the current period reached ¥9,942,001,713.50, representing a year-on-year increase of 21.28% compared to ¥8,197,667,667.88 in the same period last year[96]. - The company achieved a total sales revenue of 9.942 billion RMB in 2022, representing a growth of 21.28% compared to the previous year[74]. - Export revenue amounted to 333 million USD, reflecting a growth of 42.31% year-over-year[74]. Research and Development - Research and development expenses increased by 10% year-on-year, focusing on new product innovations in the PVA and PVB sectors[46]. - R&D investment reached 537 million yuan, a 52.03% increase year-on-year, with R&D personnel accounting for 17.44% of the total workforce[51]. - The company’s total R&D expenditure for the period was CNY 537,254,288.89, representing a 52.03% increase compared to the same period last year, and accounting for 5.4% of total revenue[158]. - The company has over 100 patents related to PVA and its derivatives, with several technologies being unique in the domestic industry[120]. Market Expansion and Strategy - The company plans to expand its market presence by increasing production capacity by 20% in the next fiscal year[46]. - The company aims to enhance its competitive edge by pursuing strategic acquisitions in the biotechnology sector[46]. - The company is actively expanding its product applications in various industries, including construction, textiles, and electronics, driven by increasing domestic demand[88]. - The company is focusing on high-value specialty PVA products and has shifted its development strategy to enhance its competitive edge in high-end applications[197]. Sustainability and Environmental Practices - The company is committed to improving its sustainability practices, targeting a 30% reduction in carbon emissions by 2025[46]. - The company implemented a wastewater recycling project, recovering 90% of water used in production, which reduced both costs and environmental impact[83]. - The company has developed a green circular economy approach by utilizing waste materials in the production process, enhancing sustainability[120]. - The company is actively developing biodegradable PVA materials, aligning with national strategies for environmental sustainability[145]. Operational Efficiency - The net cash flow from operating activities for the second quarter reached CNY 1,018,060,724.93, indicating strong operational efficiency[39]. - The company reduced costs by 34.747 million RMB through various efficiency measures[75]. - The company reported a significant reduction in inventory levels for polyvinyl alcohol, down by 35.78% compared to the previous year[129]. - The company implemented a principle of nearby delivery to enhance resource allocation efficiency, reduce sales and transportation costs, and improve overall operational effectiveness[200]. Acquisitions and Investments - The company completed the acquisition of 100% equity in Wanhui Bosheng, enhancing its PVA-PVB resin-PVB film full industry chain advantage[50]. - The company completed the acquisition of 100% equity in Wanhua Weisheng, enhancing its product variety and integrating the PVA-PVB resin-PVB film industry chain[108]. - The company acquired a 75% stake in Mingyuan Water for approximately 54.55 million, enhancing its water supply stability[133]. Challenges and Risks - The company has acknowledged potential risks in its future plans, advising investors to be cautious[5]. - The company faces high entry barriers in the PVB film industry due to significant capital investment and advanced technology requirements, limiting competition[116]. - The company’s PVB film quality lags behind international competitors, which may impact its market share in high-end segments[116].

Financial Performance - The company's operating revenue for Q3 2022 was ¥2,217,697,314.71, a decrease of 8.93% compared to ¥2,435,131,477.51 in the same period last year[6]. - Net profit attributable to shareholders was ¥324,683,837.49, an increase of 33.88% from ¥242,518,498.32 year-on-year[6]. - The basic earnings per share for the quarter was ¥0.152, reflecting a growth of 32.17% compared to ¥0.115 in the same period last year[8]. - Total operating revenue for the first three quarters of 2022 reached ¥7,278,512,618.05, an increase of 16.7% compared to ¥6,236,139,931.93 in the same period of 2021[33]. - The total operating profit for the period was approximately ¥1.56 billion, an increase from ¥856.46 million in the previous period, representing a growth of 83.5%[36]. - The net profit attributable to the parent company's shareholders reached ¥1.29 billion, compared to ¥726.64 million in the same period last year, marking a year-over-year increase of 77.9%[36]. - The total comprehensive income for the period was approximately ¥1.16 billion, up from ¥604.68 million, reflecting a growth of 92.1%[38]. - The basic and diluted earnings per share were both ¥0.610, compared to ¥0.344 in the previous year, indicating an increase of 77.5%[38]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥1,953,629,395.50, representing a 34.68% increase from ¥1,450,609,425.81 in the previous year[8]. - Cash inflows from operating activities totaled approximately ¥7.73 billion, compared to ¥5.25 billion in the previous year, representing a growth of 47.4%[42]. - The net cash flow from operating activities was approximately ¥1.95 billion, an increase from ¥1.45 billion, reflecting a growth of 34.7%[42]. - Cash and cash equivalents increased by 50.00% due to the purchase of large time deposits during the reporting period[14]. - The cash and cash equivalents at the end of the period amounted to approximately ¥179.50 million, compared to ¥254.17 million at the end of the previous year, showing a decrease of 29.4%[44]. - Total assets at the end of the reporting period were ¥13,044,418,752.69, an increase of 8.25% from ¥11,654,037,501.86 at the end of the previous year[8]. - The company's total assets as of September 30, 2022, amounted to ¥13,044,418,752.69, compared to ¥12,050,506,447.21 at the end of 2021, indicating a growth of 8.2%[28]. - Total current assets increased to ¥5,834,942,683.53 in 2022 from ¥5,103,135,448.58 in 2021, representing a rise of 14.3%[27]. Liabilities and Equity - The company's equity attributable to shareholders increased by 17.85% to ¥7,677,100,473.71 from ¥6,357,915,712.16 year-on-year[8]. - The company's equity attributable to shareholders increased to ¥7,677,100,473.71 in 2022 from ¥6,514,357,840.22 in 2021, reflecting a growth of 17.8%[28]. - Total liabilities decreased slightly to ¥5,318,330,272.67 in 2022 from ¥5,504,245,795.21 in 2021, a decline of 3.4%[28]. Research and Development - Research and development expenses surged by 64.65% as the company increased its investment in R&D during the reporting period[14]. - Research and development expenses increased significantly to ¥402,876,088.58 in 2022 from ¥244,683,734.74 in 2021, marking a rise of 64.5%[33]. Other Financial Metrics - The weighted average return on net assets increased by 0.44 percentage points to 4.18% compared to 3.74% in the same period last year[8]. - The company reported a total of ¥5,643,589.79 in non-recurring gains and losses for the quarter[11]. - The net profit after deducting non-recurring gains and losses was ¥319,040,247.70, up 35.23% from ¥235,919,329.38 in the same period last year[8]. - The company reported a tax expense of approximately ¥204.02 million, up from ¥116.81 million, reflecting an increase of 74.7%[36]. - The company recorded a 2,667.89% increase in gains from asset disposals, resulting from the disposal of inefficient assets[14]. - The company’s financial expenses decreased by 110.85%, primarily due to reduced interest expenses and the impact of exchange rate fluctuations[14]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance competitive positioning[33].